Is Recombinant Activated Factor VII a Universal Hemostatic?

  • P. Diprose
  • R. Gill
  • M. Herbertson
Conference paper


Advances in resuscitation, surgical, anesthetic, and critical care management have significantly improved outcomes after trauma or major surgery in the past two decades. However, morbidity and mortality still occur due to a wide variety of complications in the setting of trauma and major surgery. One of the foremost of these complications is continued blood loss [1, 2]. Despite best surgical practice ongoing bleeding from sites of major trauma and surgery frequently occurs due to coagulopathy [3, 4]. With laboratory testing, some of the deficits in the coagulation process can be identified and with blood bank supplies patients’ hemoglobin concentrations can be maintained and some deficits in the pathways of blood coagulation can be rectified. However, our understanding of coagulation processes is still incomplete and our ability to intervene in the setting of inadequate coagulation is limited. Furthermore, the use of large volumes of blood bank supplies, in the setting of ongoing major hemorrhage, carries its own list of complications, in particular ongoing organ damage and iatrogenic infection. Taking a broader view of the provision of health care in the context of limited resources, increasing demand for blood bank components makes ever increasing inroads into scarce supplies.


Tissue Factor Thrombin Generation Hydroxyethyl Starch Blood Coagul Fibrinolysis Recombinant FVIIa 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Gofrit ON, Leibovici D, Shapira SC, Shemer J, Stein M, Michaelson M (1997) The trimodal death distribution of trauma victims: military experience from the Lebanon War. Mil Med 162:24–26Google Scholar
  2. 2.
    Sauaia A, Moore FA, Moore EE, et al (1995) Epidemiology of trauma deaths: a reassessment. J Trauma 38: 185–193PubMedCrossRefGoogle Scholar
  3. 3.
    Cosgriff N, Moore EE, Sauaia A, Kenny-Moynihan M, Burch JM, Galloway B (1997) Predicting life-threatening coagulopathy in the massively transfused trauma patient: hypothermia and acidoses revisited. J Trauma 42: 857–861PubMedCrossRefGoogle Scholar
  4. 4.
    Attar S, Boyd D, Layne E, McLaughlin J, Mansberger AR, Cowley RA (1969) Alterations in coagulation and fibrinolytic mechanisms in acute trauma. J Trauma 9: 939–965PubMedCrossRefGoogle Scholar
  5. 5.
    Kaufmann CR, Dwyer KM, Crews JD, Dols SJ, Trask AL (1997) Usefulness of thrombelastography in assessment of trauma patient coagulation. J Trauma 42: 716–720PubMedCrossRefGoogle Scholar
  6. 6.
    Diness V, Bregengaard C, Erhardtsen E, Hedner U (1992) Recombinant human factor VIIa (rFVIIa) in a rabbit stasis model. Thromb Res 67: 233–241PubMedCrossRefGoogle Scholar
  7. 7.
    Hedner U, Glazer S, Pingel K, et al (1988) Successful use of recombinant factor VIIa in patient with severe haemophilia A during synovectomy. Lancet 2: 1193PubMedCrossRefGoogle Scholar
  8. 8.
    Glazer S, Hedner U, Falch JF (1995) Clinical update on the use of recombinant factor VII. Adv Exp Med Biol 386: 163–174PubMedCrossRefGoogle Scholar
  9. 9.
    Green D, Lechner K (1981) A survey of 215 non-hemophilic patients with inhibitors to Factor VIII. Thromb Haemost 45: 200–203PubMedGoogle Scholar
  10. 10.
    Hoffman M, Monroe DM, III, Roberts HR (1998) Activated factor VII activates factors IX and X on the surface of activated platelets: thoughts on the mechanism of action of high-dose activated factor VII. Blood Coagul Fibrinolysis 9 (suppl 1): S61 - S65PubMedGoogle Scholar
  11. 11.
    Hoffman M, Monroe DM, Oliver JA, Roberts HR (1995) Factors IXa and Xa play distinct roles in tissue factor-dependent initiation of coagulation. Blood 86: 1794–1801PubMedGoogle Scholar
  12. 12.
    Bajzar L, Manuel R, Nesheim ME (1995) Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor. J Biol Chem 270: 14477–14484PubMedCrossRefGoogle Scholar
  13. 13.
    Bouma BN, Meijers JC (1999) Fibrinolysis and the contact system: a role for factor XI in the down-regulation of fibrinolysis. Thromb Haemost 82: 243–250PubMedGoogle Scholar
  14. 14.
    Gubler KD, Gentilello LM, Hassantash SA, Maier RV (1994) The impact of hypothermia on dilutional coagulopathy. J Trauma 36: 847–851PubMedCrossRefGoogle Scholar
  15. 15.
    Jamnicki M, Zollinger A, Seifert B, Popovic D, Pasch T, Spahn DR (1998) Compromised blood coagulation: an in vitro comparison of hydroxyethyl starch 130/0.4 and hydroxyethyl starch 200/0.5 using thrombelastography. Anesth Analg 87: 989–993PubMedGoogle Scholar
  16. 16.
    Jamnicki M, Zollinger A, Seifert B, Popovic D, Pasch T, Spahn DR (1998) The effect of potato starch derived and corn starch derived hydroxyethyl starch on in vitro blood coagulation. Anaesthesia 53: 638–644PubMedCrossRefGoogle Scholar
  17. 17.
    Bergstein JM, Slakey DP, Wallace JR, Gottlieb M (1996) Traumatic hypothermia is related to hypotension, not resuscitation. Ann Emerg Med 27: 39–42PubMedCrossRefGoogle Scholar
  18. 18.
    Gando S, Tedo I, Kubota M (1992) Post-trauma coagulation and fibrinolysis. Crit Care Med 20: 594–600PubMedCrossRefGoogle Scholar
  19. 19.
    Kapsch DN, Metzler M, Harrington M, Mitchell FL, Silver D (1984) Fibrinolytic response to trauma. Surgery 95: 473–478PubMedGoogle Scholar
  20. 20.
    Hedner U, Erhardtsen E (2002) Potential role for rFVIIa in transfusion medicine. Transfusion 42: 114–124PubMedCrossRefGoogle Scholar
  21. 21.
    Monroe DM, Hoffman M, Oliver JA, Roberts HR (1997) Platelet activity of high-dose factor VIIa is independent of tissue factor. Br J Haematol 99: 542–547PubMedCrossRefGoogle Scholar
  22. 22.
    Martinowitz U, Kenet G, Segal E, et al (2001) Recombinant activated factor VII for adjunctive hemorrhage control in trauma. J Trauma 51: 431–438PubMedCrossRefGoogle Scholar
  23. 23.
    Friederich PW, Geerdink MG, Spataro M, et al (2000) The effect of the administration of recombinant activated factor VII (NovoSeven) on perioperative blood loss in patients undergoing transabdominal retropubic prostatectomy: the PROSE study. Blood Coagul Fibrinolysis 11 (suppl 1): 5129–5132Google Scholar
  24. 24.
    Al Douri M, Shaft T, Al Khudairi D, et al (2000) Effect of the administration of recombinant activated factor VII (rFVIIa; NovoSeven) in the management of severe uncontrolled bleeding in patients undergoing heart valve replacement surgery. Blood Coagul Fibrinolysis 11 (suppl 1): 5121 - S127Google Scholar
  25. 25.
    Sumner WT, Monroe DM, Hoffman M (1996) Variability in platelet procoagulant activity in healthy volunteers. Thromb Res 81: 533–543PubMedCrossRefGoogle Scholar
  26. 26.
    Erhardtsen E (2000) Pharmacokinetics of recombinant activated factor VII (rFVIIa). Semin Thromb Hemost 26: 385–391PubMedCrossRefGoogle Scholar
  27. 27.
    Hedner U, Ingerslev J (1998) Clinical use of recombinant FVIIa (rFVIIa). Transfus Sci 19: 163–176PubMedCrossRefGoogle Scholar
  28. 28.
    Diprose P, Herbertson MJ, O’Shaughnessy D, Gill R (2002) Recombinant factor VIIa for severe cardiac surgical bleeding - A review of our first seven patients (abstract presented at Rome NATA meeting )Google Scholar
  29. 29.
    Dam-Mieras MC, Muller AD, van Deijk WA, Hemker HC (1985) Clotting factors secreted by monocytes and macrophages: analytical considerations. Thromb Res 37: 9–19PubMedCrossRefGoogle Scholar
  30. 30.
    Melton LG, Thompson CM, Ezban M (1999) Response of rFVIIa concentrate on hemostasis in hemophilia (abstract). Blood 94 (Suppl 1): 228Google Scholar
  31. 31.
    Martinowitz U, Holcomb JB, Pusateri AE, et al (2001) Intravenous rFVIIa administered for hemorrhage control in hypothermic coagulopathic swine with grade V liver injuries. J Trauma 50: 721–729PubMedCrossRefGoogle Scholar
  32. 32.
    Schreiber MA, Holcomb JB, Hedner U, Brundage SI, Macaitis JM, Hoots K (2002) The effect of recombinant factor VIIa on coagulopathic pigs with grade V liver injuries. J Trauma 53: 252–257PubMedCrossRefGoogle Scholar
  33. 33.
    Lynn M, Jerokhimov I, Jewelewicz D, et al (2002) Early use of recombinant factor VIIa improves mean arterial pressure and may potentially decrease mortality in experimental hemorrhagic shock: a pilot study. J Trauma 52: 703–707PubMedCrossRefGoogle Scholar
  34. 34.
    Kenet G, Walden R, Eldad A, Martinowitz U (1999) Treatment of traumatic bleeding with recombinant factor VIIa. Lancet 354: 1879PubMedCrossRefGoogle Scholar
  35. 35.
    Hendriks HG, van der Maaten JM, de Wolf J, Waterbolk TW, Slooff MJ, van der Meer J (2001) An effective treatment of severe intractable bleeding after valve repair by one single dose of activated recombinant factor VII. Anesth Analg 93: 287–289PubMedGoogle Scholar
  36. 36.
    Dietrich W, Spannagl M (2002) Caveat against the use of activated recombinant factor VII for intractable bleeding in cardiac surgery. Anesth Analg 94: 1369–1370PubMedCrossRefGoogle Scholar
  37. 37.
    Jeffers L, Chalasani N, Balart L, Pyrsopoulos N, Erhardtsen E (2002) Safety and efficacy of recombinant factor VIIa in patients with liver disease undergoing laparoscopic liver biopsy. Gastroenterology 123: 118–126PubMedCrossRefGoogle Scholar
  38. 38.
    Hendriks HG, Meijer K, de Wolf JT, et al (2001) Reduced transfusion requirements by recombinant factor VIIa in orthotopic liver transplantation: a pilot study. Transplantation 71: 402–405PubMedCrossRefGoogle Scholar
  39. 39.
    Hendriks HG, Meijer K, de Wolf JT, et al (2002) Effects of recombinant activated factor VII on coagulation measured by thromboelastography in liver transplantation. Blood Coagul Fibrinolysis 13: 309–313PubMedCrossRefGoogle Scholar
  40. 40.
    White B, McHale J, Ravi N, et al (1999) Successful use of recombinant FVIIa ( Novoseven) in the management of intractable post-surgical intra-abdominal haemorrhage. Br J Haematol 107: 677–678Google Scholar
  41. 41.
    Vlot AJ, Ton E, Mackaay AJ, Kramer MH, Gaillard CA (2000) Treatment of a severely bleeding patient without preexisting coagulopathy with activated recombinant factor VII. Am J Med 108: 421–423PubMedCrossRefGoogle Scholar
  42. 42.
    Erhardtsen E (2002) Ongoing NovoSeven((R)) trials. Intensive Care Med 28 (Suppl 2): S248 - S256PubMedCrossRefGoogle Scholar
  43. 43.
    Friederich PW, Levi M, Bauer KA, et al (2001) Ability of recombinant factor VIIa to generate thrombin during inhibition of tissue factor in human subjects. Circulation 10: 25552559Google Scholar
  44. 44.
    Bauer KA, Kass BL, ten Cate H, Hawiger JJ, Rosenberg RD (1990) Factor IX is activated in vivo by the tissue factor mechanism. Blood 76: 731–736PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2003

Authors and Affiliations

  • P. Diprose
  • R. Gill
  • M. Herbertson

There are no affiliations available

Personalised recommendations